Eidos Therapeutics Inc (EIDX) Quote

Just In: $EIDX SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Eidos Therapeutics, Inc. (Nasdaq - EIDX)

BALA CYNWYD, PA / ACCESSWIRE / October 5, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Eidos Therapeutics, Inc. ("Eidos" or the "Company") (NASDAQ:EIDX) for possible breaches of fiduciary duty and other vi...

Read the whole news EIDX - SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Eidos Therapeutics, Inc. (Nasdaq - EIDX)

NEWS: $EIDX Why Eidos Therapeutics Stock Is Skyrocketing Today

Shares of Eidos Therapeutics (NASDAQ: EIDX) were skyrocketing 41.1% higher as of 11:50 a.m. EDT on Monday. The huge gain came after BridgeBio Pharma (NASDAQ: BBIO) announced plans to acquire Eidos. BridgeBio already owns a major stake in Eidos. It's now seeking to buy th...

Read the whole news EIDX - Why Eidos Therapeutics Stock Is Skyrocketing Today

News; $EIDX (EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics; Are Shareholders Getting a Fair Deal?

(EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, Oct. 5, 2020 SAN DIEGO , Oct. 5, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an i...

Got this from EIDX - (EIDX) Alert: Johnson Fistel Investigates Proposed Sale of Eidos Therapeutics; Are Shareholders Getting a Fair Deal?

News: $EIDX CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-...

Got this from EIDX - CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

News: $EIDX BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-...

Got this from EIDX - BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

News: $EIDX Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares

Forms Special Committee of Independent and Disinterested Directors to Review Proposal Advises Stockholders Take No Action at this Time Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the “Company”) today confirmed that it has received a non-binding proposal dated August 8, 2...

Got this from Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares

News: $EIDX INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc. (“Eidos” or “the Company”) (NASDAQ: EIDX ) for violations of §§10(b) and 20(a) of the Secu...

Got this from https://marketwirenews.com/news-releases/investigation-reminder-the-schall-law-firm-announces-it-is-investigating-claims-against-eidos-therapeutics-inc-and-encourages-investors-with-losses-in-excess-of-100-000-to-contact-the-firm-7952186.html

EIDX buy 23.40



normal chart







log chart

Looking good so far,

Good eyesight!

Earning release Feb. 5th

I see good times ahead. Phase 2 reads out upcoming.. I have good feelings about it

What si the news on EIDX? Anything Positive?

Going under $10 soon?

Shorts are winning here in this POS

I do not know, but we should soon find out.
I suspect some over reaction to internal news.

What is going here? Why is this getting pummeled?

Interesting possibilities here.